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Abst rac t
Introduction: Research has demonstrated a link between psoriasis and a multitude of psychological impairments; 
however, relatively few studies have examined the importance of site of skin lesions for negative psychological 
outcomes in psoriasis patients.
Aim: To investigate relationships between anatomical location of psoriatic lesions and experiences of stigmatiza-
tion, negative emotional attitude towards the body, depression and social anxiety.
Material and methods: Adult psoriasis patients (N = 193) completed the Stigmatization Scale, the Body Emotions 
Scale, the Beck Depression Inventory and the Social Anxiety Questionnaire. The body surface area index was used 
to assess the location and extent of psoriasis.
Results: Feelings of stigmatization were found to be most closely related to the presence of psoriatic lesions on the 
chest, and the arms and hands. Higher levels of social anxiety were found to be most closely related to the location 
of psoriatic lesions on the head and neck. Negative emotional attitude towards the body was found to be most 
closely related to the location of psoriatic lesions on the arms and hands, and on the head and neck. Higher levels 
of depressive symptoms were most closely related to the presence of psoriatic lesions on the head and neck, the 
arms and hands, and the genital area.
Conclusions: The presence of psoriatic lesions on the head, neck, and chest, and also on the arms and hands and 
the genital area, should alert clinicians to a higher risk of psychological impairments. This may help to better rec-
ognize and prevent cumulative life course impairment.
Key words: body image, depression, psoriasis, social anxiety, stigmatization.
Introduction
Psoriasis is a chronic inflammatory skin disease, affect-
ing men and women equally, with an estimated prevalence 
of 2–3% in Europeans [1]. Psoriasis may involve all sites of 
the body, including facial and genital skin. As with other 
dermatoses, visible disfigurement can serve as a stressor in 
itself and, furthermore, triggers a negative reaction in oth-
ers, resulting in feelings of stigmatization [2, 3], which jointly 
can cause much of the readily measurable psychosocial bur-
den of the disease. Psoriasis strongly affects many facets 
of patients’ quality of life, including physical, psychological, 
social, sexual, and economic aspects [4–7].
To date, an extensive literature describes the co-
occurrence of psoriasis and depression, anxiety, suicidal 
ideation, and negative body image [6–12]. However, the 
negative impact of psoriasis on patients’ lives, includ-
ing psychosocial disability, is often unrecognized and 
under-treated [13, 14]. This is an important issue to con-
sider, because psychological comorbidities associated 
with psoriasis have been found to be associated with poor 
treatment adherence, poor therapeutic response, and in-
ferior outcomes [15–17]. Moreover, it has been found that 
in patients with psoriasis, depression is associated with 
increased risk of myocardial infarction, stroke, and cardio-
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vascular death, especially during acute depression [18]. 
It is important to better understand key risk factors for 
psychological impairments associated with psoriasis, 
which may help to identify individuals who are more vul-
nerable to the cumulative impact of psoriasis.
Remarkably few data exist on the relationships between 
anatomical location of psoriatic lesions and psychological 
comorbidities. Nonetheless, to date, it has been reported 
that psychiatric morbidities were found to be higher in der-
matological patients with lesions localized on the face and/
or hands as compared to the patients without lesions on 
these parts of the body [19]. It has also been reported that 
skin lesions on the visible parts of the body were associated 
with poor physical and mental health in psoriasis patients 
[20]. Some authors found, however, that patients with pso-
riasis and atopic dermatitis with genital involvement had 
significantly higher feelings of stigmatization than those 
with the visible and the invisible (under clothes) regions af-
fected [21]. In contrast, in one study, no relationship was 
found between location of psoriatic lesions and feelings 
and experiences of stigmatization [2]. In sum, relatively few 
studies have examined the relationships between anatomi-
cal location of skin lesions and psychological impairments 
in psoriasis patients. Furthermore, existing research has in-
cluded various groups of dermatological patients and the 
results varied across the studies. It is important to better 
understand which factors are associated with negative 
psychological outcomes in psoriasis patients. Knowledge 
of such factors, and especially of those that can readily be 
seen by physicians during a routine clinical examination, 
might facilitate the identification of patients with a higher 
risk for psychological impairments.
Indeed, although studies that have examined the rela-
tionship between site of skin lesions and risk of psychologi-
cal impairments in patients with psoriasis are sparse, a re-
lationship between the disease severity and mental health 
has been revealed in many studies. Evidence, however, has 
demonstrated that clinician-assessed objective severity of 
psoriasis is not or is poorly associated with psychological 
outcome variables [22–26]. Magin et al. reported that self-
assessed rather than objective severity is associated with 
psychological burden of skin diseases, and models of asso-
ciation with psychological morbidity in patients with a dis-
ease such as psoriasis are likely to be improved by inclusion 
of self-measured disease severity [26]. The patient’s sub-
jective perception of the skin disease does not necessarily 
align with the perception of the clinician or with objective 
measures of severity, but may have importance in explaining 
the psychological burden of the disease. According to these 
conclusions, in this study we tested associations between 
self-assessed disease severity and psychological outcomes.
Aim
The aim of this study was to investigate the impor-
tance of location of the skin lesions for experiences of 
stigmatization, negative body image emotions, social 
anxiety and depressive symptoms in patients with pso-
riasis.
Material and methods
Participants and procedure
Subjects were recruited from the Dermatology Clinic 
of the Silesian Medical University in Katowice, the Polish 
Association of Psoriasis Patients in Bydgoszcz and the 
Union of Psoriasis Associations in Poland. Inclusion cri-
teria were age ≥ 18, psoriasis diagnosed by a dermatolo-
gist, at least 1 year of disease duration, and informed 
consent. Ethical approval was granted by the Ethics Com-
mittee of the University of Silesia. The recruitment took 
place between November 2014 and February 2015.
In total, 193 of 202 received responses fulfilled the 
criteria adopted in this study. More than one-fifth of the 
respondents (21.2%) were members of psoriasis patients’ 
associations. No statistically significant differences were 
found between the members (n = 41) vs. the non-mem-
bers (n = 152) regarding socio-demographic, psychologi-
cal, and psoriasis-related variables (all p-values ≥ 0.10).
Measures
Depression was measured by the Beck Depression In-
ventory (BDI) [27, 28]. The BDI is a self-report scale con-
sisting of 21 items. All of the 21 items corresponding to 
the depressive symptoms are summed to give a single 
score for the BDI. The total scores can range from 0 to 
63, with higher scores indicating more severe depressive 
symptoms. The Polish validated version shows good reli-
ability and content validity [29]. A score of 0–11 indicates 
no or minimal depression; 12–26 indicates mild depres-
sion; 27–49 indicates moderate depression; 50–63 indi-
cates severe depression. The reliability of the BDI in the 
current study was α = 0.92.
The Social Anxiety Questionnaire (SAQ) is a 12-item, 
Likert-type self-report measure of social anxiety accord-
ing to the Clark and Wells’ model of social phobia [30]. 
The SAQ consists of three factors: Symptoms of Social 
Anxiety (e.g., “The anxiety which I feel in social situations 
significantly disrupts my occupational or academic func-
tioning and other social activities”), Negative Self-image 
(e.g., “I think about myself as an ineffectual, socially un-
attractive person”), and Excessive Processing of the Self 
as a Social Object (e.g., “During social situations I keep 
thinking about how I look and how others judge me”). 
The SAQ shows good psychometric properties [31]. Prior 
research with this measure has indicated good reliability 
and construct validity. The SAQ was significantly corre-
lated with anxiety, self-focused rumination, feelings of 
loneliness and low self-esteem. In the current sample the 
internal consistency for the SAQ was α = 0.95, and for 
the subscales it ranged from 0.87 to 0.89.
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The Stigmatization Scale is a 6-item scale assessing 
the experiences and feelings of stigmatization caused 
by skin diseases [32]. Respondents answered the state-
ments on a 4-grade scale, ranging from 0 (not at all) to 
3 (always). The total scores can range from 0 to 18, with 
higher scores indicating higher levels of stigmatization. 
Example of an item: “Other people avoid me due to my 
skin disease”. We used the Polish validated version of 
the scale [33]. The internal consistency of the scale in the 
current sample was α = 0.88.
The emotional attitude towards the body was mea-
sured using the 9-item Body Emotions Subscale of the 
Body Ego Questionnaire [34]. Patients answered the 
statements on a 5-point scale. The Body Emotions Sub-
scale ranges from 9 to 45, with higher scores reflecting 
a more negative emotional attitude toward the body. An 
example of an item from the Body Emotions Subscale is 
as follows: “Sometimes I hate the way I look”. In our sam-
ple the internal consistency for this subscale was = 0.90.
Sociodemographic data were collected along with 
baseline disease characteristics such as age at onset of 
psoriasis, diagnosis by physician, duration of the disease, 
family history of psoriasis, and self-assessed severity of 
the disease. The disease severity was defined based on 
the body surface area (BSA) index. Body surface area is 
a simple and commonly used instrument referring to the 
percentage of body surface area involvement [35]. Body 
surface area is also used as a self-reported measure of 
the severity of psoriasis [36, 37]. Patients were instructed 
to estimate psoriasis coverage using the rule of nine and 
the palmar site of the hand as equivalent to 1% of the 
BSA. The respondents reported the surface area of their 
skin affected by psoriasis including head and neck, arms 
and hands, chest, abdomen, upper back, lower back, 
thighs, lower legs and genital area. In general, BSA un-
der 5% indicates mild involvement, 5–10% is defined as 
moderate, and over 10% is considered severe.
Statistical analysis
Correlations between variables were calculated using 
Pearson’s correlation coefficient. Group differences were 
analyzed using the t-test and c2 test. To identify the loca-
tion of skin lesions associated with psychological impair-
ments four stepwise multiple linear regression models 
with depression, social anxiety, stigmatization and nega-
tive emotional attitude towards the body as dependent 
variables were performed. All statistical analyses were 
run under the statistical package Statistica (StatSoft 
Inc.), version 12.
Results
Characteristics of the sample
The sample consisted of 193 psoriasis patients, and 
68.4% (n = 132) of them were women. As shown in Table 
1, participants’ age range was 20–67 years (M = 36.4 
±12.1). The mean age at onset of psoriasis was 19.6 ±10.6 
years, varying between 0 and 54 years of age. The mean 
duration of psoriasis was 16.8 ±11.9 years, varying between 
1 and 53 years. Plaque psoriasis was the most common 
type of psoriasis, which was reported in 175 (90.7%) 
cases. More than one-third of the respondents (36.8%) 
reported nail involvement. In addition, joint complaints 
were present in 18.6% of the patients. Table 2 shows the 
number of patients with involvement of particular body 
sites. Almost half of the respondents (48.7%) reported 
psoriatic involvement of the genital skin, whereas more 
than half of the respondents (81.3%) reported presence 
of skin lesions on the head and neck (Table 2).
At the time of this study, 84 (43.5%) patients reported 
mild, and 31 (16.1%) patients presented moderate de-
pressive symptoms as defined by the BDI. High levels of 
social anxiety were observed in 64 (33.2%) cases.
Table 1. Baseline characteristics (N = 193)
Parameter Value
Age, mean ± SD [years] 34.6 ±12.1
Sex, n (%):
Female 132 (68.4)
Male 61 (31.6)
Education, n (%):
Primary 2 (1.0)
Technical/vocational 21 (11.0)
Secondary 85 (44.0)
Higher education 85 (44.0)
Marital status, n (%):
Single 62 (32.1)
Married/cohabiting 104 (53.9)
Divorced 21 (10.9)
Widowed 6 (3.1)
Work, n (%):
Employed 129 (66.8)
Unemployed 19 (9.8)
Student 24 (12.4)
Retired 21 (10.9)
Age at onset of psoriasis, mean ± SD [years] 19.6 ±10.6
Duration of psoriasis, mean ± SD [years] 16.8 ±11.9
Body surface area (BSA), mean (range) 21.2 (1–82)
BSA involvement, n (%):
< 5% 30 (15.5)
5–10% 52 (27.0)
> 10% 111 (57.5)
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 Associations between location of skin lesions  
and psychological outcomes
Psoriatic involvement of all investigated parts of the 
body was statistically significantly related to feelings of 
stigmatization and negative emotional attitude towards 
the body. As shown in Table 2, the strongest association 
was observed between experiences of stigmatization 
and presence of psoriatic lesions on the arms and hands 
(r = 0.34; p < 0.0001), and the chest (r = 0.33; p < 0.0001). 
The negative emotional attitude towards the body was 
most closely related to the presence of lesions on the 
arms and hands (r = 0.27; p < 0.0001), the head and neck 
(r = 0.25; p < 0.0001), and the chest (r = 0.24; p < 0.001). 
Depressive symptoms were significantly related to the 
presence of skin lesions on the head and neck (r = 0.28; 
p < 0.0001), the genital skin (r = 0.25; p < 0.0001), and 
the upper back (r = 0.25; p < 0.0001). Social anxiety was 
significantly associated with the presence of psoriatic le-
sions on the head and neck (r = 0.18; p < 0.05), and the 
chest (r = 0.15; p < 0.05). Moreover, subjective severity of 
the disease based on body surface area involvement was 
significantly associated with all of the psychological out-
come variables (Table 2). Correlation coefficients ranged 
from 0.15 to 0.31 (p < 0.05).
To examine the relative contribution of location of 
psoriatic lesions to depression, social anxiety, negative 
emotional attitude towards the body and stigmatization, 
four stepwise multiple linear regressions were performed. 
The results are presented in Table 3. As shown in this 
table, the location of psoriatic lesions on the head and 
neck (p < 0.01), the genital skin (p < 0.05), and on the 
arms and hands (p < 0.05) was most closely associated 
with depression, accounting for 12% of the variance. The 
main contributor to depression was the presence of le-
sions on the head and neck, accounting for 8% of the vari-
ance in the BDI scores.
Regression analysis for social anxiety revealed that 
only the location of psoriatic lesions on the head and 
neck was statistically significant in accounting for the 
variance of this variable (approximately 3%). Other body 
regions did not reach statistical significance.
Regression analysis for feelings of stigmatization in-
dicated that the location of psoriatic lesions on the arms 
and hands (p < 0.01), and the chest (p < 0.01) was sta-
tistically significant in accounting for the variance (ap-
proximately 15% of explained variance).
Regression analysis revealed that the main contribu-
tors to the negative emotional attitude towards the body 
were the presence of skin lesions on the arms and hands 
(p < 0.01), and presence on the head and neck (p < 0.01), 
accounting for 12% of the variance.
Discussion
Although there is strong evidence for the link be-
tween psoriasis and psychological disorders [6–10] 
relatively few studies have examined the relationships 
between anatomical location of skin lesions and psycho-
logical comorbidities in patients with psoriasis. The re-
sults of the present study highlight the importance of the 
occurrence of lesions in different body regions for feel-
ings and experiences of stigmatization, negative emo-
tional attitude towards the body, social anxiety and de-
pressive symptoms. The location of psoriatic lesions on 
the head and neck was the main contributor to depres-
sion, social anxiety and negative emotional attitude to 
the body. The location of lesions on the arms and hands 
was a significant contributor to feelings of stigmatiza-
tion, negative emotional attitude toward the body, and 
depression. Additionally, the genital involvement makes 
a significant contribution to the variance in depression, 
whereas the presence of psoriatic lesions on the chest 
Table 2. Correlations between site of psoriatic lesions and depression, social anxiety, experiences of stigmatization and 
negative emotional attitude to the body
Involvement of particular 
body sites
N (%) Depression Social  
anxiety
Stigmatization Negative emotional 
attitude to the body
Head and neck 157 (81.3) 0.28*** 0.18* 0.15* 0.25***
Arms and hands 164 (85.0) 0.22** 0.13 0.34*** 0.27***
Chest 101 (52.3) 0.24** 0.15* 0.33*** 0.24**
Abdomen 111 (57.5) 0.19** 0.13 0.20** 0.15*
Upper back 98 (50.8) 0.25*** 0.10 0.16* 0.21**
Lower back 130 (67.4) 0.19** 0.12 0.26*** 0.23**
Thighs 108 (56.0) 0.13 0.13 0.28*** 0.21**
Knees, lower legs, ankles 117 (60.6) 0.16* 0.05 0.26*** 0.17*
Genital area 94 (48.7) 0.25*** 0.13 0.16* 0.22**
BSA total 193 (100) 0.28*** 0.15* 0.31*** 0.30***
***p < 0.001, **p < 0.01, *p < 0.05.
Advances in Dermatology and Allergology 1, February / 201864
Patryk Łakuta, Kamil Marcinkiewicz, Beata Bergler-Czop, Ligia Brzezińska-Wcisło, Anna Słomian
was a significant contributor to experiences of stigmati-
zation. Moreover, according to current knowledge [6–10], 
our results show high rates of psychological impairments 
in patients with psoriasis. In this study 16.1% of patients 
reported moderate depressive symptoms. Mild depres-
sive symptoms were present in 43.5% of the patients. 
Furthermore, high levels of social anxiety were observed 
in 33.2% of the respondents.
To date, only a few studies have been conducted on 
the relationship between location of psoriatic lesions and 
psychological impairment in patients with psoriasis. How-
ever, it has been reported that patients with visible pso-
riatic lesions reported poorer physical and mental health 
[20], which is consistent with the findings of our study. In 
addition, our results are in agreement with the findings re-
ported by Picardi et al. [19], who found that in dermatologi-
cal patients the presence of skin lesions localized on the 
face and hands is associated with a very large increase in 
the prevalence of psychiatric disorders. Furthermore, our 
results indicated that genital involvement may be a risk 
factor for depression in patients with psoriasis. We also 
detected that the genital involvement is significantly re-
lated to feelings of stigmatization, which is consistent with 
previous research, where dermatological patients with 
genital lesions felt significantly more stigmatized than 
those without genital skin affected [21]. Moreover, these 
results are also in line with previous findings highlighting 
the association between the involvement of the genital 
area and poor quality of life, higher levels of psychological 
distress, and sexual dysfunction [38–40].
The unique contribution of this study is the analysis 
of patients’ subjective perceptions of their skin disease 
that allowed for identification of psychologically sensitive 
anatomic locations of skin lesions associated with feel-
ings of stigmatization, depressive symptoms, negative 
body-related emotions, and social anxiety. However, our 
results need to be viewed in the light of several limita-
tions. First, our study was cross-sectional; therefore, we 
cannot prove causality, and the findings need to be rep-
licated in a prospective study. Second, women are over-
represented in our sample (68.4% as opposed to 32.6%), 
which may limit the generalizability of the results. More-
over, our sample also included the members of psoriasis 
patients’ associations (21.2% of the sample). It may be 
speculated that these patients may have (by the very fact 
of their membership) considerable concern regarding 
their disease or they might suffer from more severe pso-
riasis and/or have a greater psychosocial burden of the 
disease. However, in this study no significant differences 
were found between the members vs. the non-members. 
Finally, a limitation of this study is the exclusive reliance 
on the self-report questionnaires. Future research could 
extend our findings by including both clinician-assessed 
location and severity of psoriatic lesions and those self-
assessed by patients.
Conclusions
We identified ‘sensitive’ body regions affected by 
psoriasis associated with negative mental health, in-
cluding symptoms of depression, social anxiety, negative 
emotions about one’s own appearance, and feelings of 
stigmatization. The most important result of our study is 
that the presence of psoriatic lesions on the head, neck, 
Table 3. Results from four multiple linear regression models with depression, social anxiety, stigmatization  
and negative emotional attitude toward the body as dependent variables
Variable β ΔR2 FΔR2 F R2 Adj. R2
Depression: 9.71*** 0.14 0.12
Head and neck 0.23** 0.08 15.75***
Genital area 0.16* 0.04 7.78**
Arms and hands 0.15* 0.02 4.58*
Social anxiety: 4.30* 0.04 0.03
Head and neck 0.17* 0.03 5.95*
Chest 0.11 0.01 2.59
Stigmatization: 17.57*** 0.16 0.15
Arms and hands 0.24** 0.11 24.33***
Chest 0.23** 0.05 9.69**
Negative emotional attitude to the body: 9.74*** 0.14 0.12
Arms and hands 0.22** 0.08 15.21***
Head and neck 0.20** 0.05 10.90**
Genital area 0.11 0.01 2.14
***p < 0.001, **p < 0.01, *p < 0.05.
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and chest, and also on the arms and hands and in the 
genital area, should alert clinicians to the higher risk for 
psychological impairments in patients with psoriasis. 
This may help to better recognize the problem and ear-
lier in the disease course provide patients comprehensive 
management to prevent cumulative life course impair-
ment in psoriasis. Future research should aim to further 
explore the nature of the relationship between site of 
skin lesions and psychological impairments in patients 
with psoriasis.
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